Factor XIa and tissue factor activity in patients with coronary artery disease

Saulius Butenas; Anetta Undas; Matthew T Gissel; Konstanty Szuldrzynski; Krzysztof Zmudka; Kenneth G Mann

doi:10.1160/TH07-08-0499

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(01): 142-149
DOI: 10.1160/TH07-08-0499

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Factor XIa and tissue factor activity in patients with coronary artery disease

Authors

Saulius Butenas

¹University of Vermont, Department of Biochemistry, Burlington, Vermont, USA
Anetta Undas

²Institute of Cardiology
Matthew T Gissel

¹University of Vermont, Department of Biochemistry, Burlington, Vermont, USA
Konstanty Szuldrzynski

³Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
Krzysztof Zmudka

²Institute of Cardiology
Kenneth G Mann

¹University of Vermont, Department of Biochemistry, Burlington, Vermont, USA

Abstract

Summary

It has been established that inflammation and enhanced procoagulant activity are associated with the pathogenesis of atherosclerotic vascular disease. We evaluated and compared the contributions of the factor (F)XIa and tissue factor (TF) activity in plasma of patients with coronary artery disease (CAD). Citrate plasma was obtained prior to therapy from 53 patients with stable angina (29 with a history of previous myocardial infarction; CAD-MI) and 30 with acute coronary syndrome (ACS) within 12 hours from pain onset. Four ACS patients treated with heparin were excluded. FXIa andTF activity were determined in clotting assays based upon the prolongation of clotting time by inhibitory monoclonal antibodies. Twenty-five of 26ACS patients (96%) and 22 of 29 CAD-MI patients (76%) had quantifiable FXIa (50 ± 33 and 42 ± 45pM, respectively).Ten of 26 (38%) ACS patients and only three of 53 (6%) stable CAD patients showedTF activity (<0.4pM). No FXIa or TF activity was observed in agematched healthy controls (n=12).For both CAD-MI andACS patients, there were correlations (p<0.05) between FXIa and interleukin-6 (R²= 0.59 and 0.39, respectively) and between FXIa and TAT (R²= 0.64 and 0.63, respectively). In conclusion, the majority of ACS and CAD-MI patients have circulating FXIa that correlates with markers of coagulation and inflammation.

Keywords

Coronary artery disease - factor XIa - tissue factor - inflammation markers - coagulation markers

Full Text

References

References
1 Worthley SG, Osende JI, Helft G. et al. Coronary artery disease: pathogenesis and acute coronary syndromes. Mt Sinai J Med 2001; 68: 167-181.
2 Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2: 113-121.
3 Manten A, de Winter RJ, Minnema MC. et al. Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 1998; 40: 389-395.
4 Cesari M, Penninx BW, Newman AB. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322.
5 Bevilacqua MP, Pober JS, Majeau GR. et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
6 Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
7 Ehlers R, Buttcher E, Eltzschig HK. et al. Correlation between ST-T-segment changes with markers of hemostasis in patients with acute coronary syndromes. Cardiology 2002; 98: 40-45.
8 Li YH, Teng JK, Tsai WC. et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-1548.
9 Morange PE, Bickel C, Nicaud V. et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 2006; 26: 2793-2799.
10 Derhaschnig U, Laggner AN, Roggla M. et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 2002; 48: 1924-1930.
11 Morange PE, Blankenberg S, Alessi MC. et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5: 475-482.
12 van der Putten RF, te Velthuis HT, de Zwaan C. et al. State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain. Br J Haematol 2005; 131: 91-99.
13 Campo G, Valgimigli M, Ferraresi P. et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 2006; 26: 2800-2806.
14 Minnema MC, Peters RJ, De Winter R. et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2489-2493.
15 Scott CF, Schapira M, James HL. et al. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-852.
16 Wuillemin WA, Minnema M, Meijers JC. et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-1526.
17 Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-4592.
18 Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-6508.
19 Butenas S, Dee JD, Mann KG. The function of factor XI in tissue factor-initiated thrombin generation. J Thromb Haemost 2003; 1: 2103-2111.
20 Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4: 1747-1755.
21 Colman RW, Clowes AW, George JN. et al. Overview of hemostasis. In: Hemostasis and thrombosis basic principles and clinical practice. Lippincott Williams & Wilkins. 2006: 3-16.
22 Gailani D, Broze GJ Jr.. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
23 Ratnoff OD, Coply JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613.
24 Halbmayer WM, Mannhalter C, Feichtinger C. et al. Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wien Med Wochenschr 1993; 143: 43-50.
25 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62: 248-255.
26 Zito F, Lowe GD, Rumley A. et al. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002; 165: 153-158.
27 Colhoun HM, Zito F, Norman CN. et al. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363-369.
28 Renne T, Pozgajova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
29 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
30 Cooper JA, Miller GJ, Bauer KA. et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-2822.
31 Lowe GD, Rumley A, McMahon AD. et al. Interleukin- 6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-1534.
32 Altieri P, Devoto E, Spallarossa P. et al. Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity. Thromb Res 2005; 115: 65-72.
33 Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
34 Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci USA 2007; 104: 12855-12860.
35 Morrissey JH, Macik BG, Neuenschwander PF. et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
36 Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Membrane-bound and soluble tissue factor – fuse and fire extinguisher. Blood 2004; 104 Abstract 39a.
37 del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
38 Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
39 Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
40 Wuillemin WA, Hack CE, Bleeker WK. et al. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb Haemost 1996; 76: 549-555.
41 Holmes MB, Schneider DJ, Hayes MG. et alG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102: 2051-2057.